GSK PLC Sponsored ADR $GSK Holdings Boosted by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. raised its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 8.0% in the third quarter, Holdings Channel reports. The institutional investor owned 211,232 shares of the pharmaceutical company’s stock after acquiring an additional 15,642 shares during the period. GSK comprises about 1.9% of Keystone Financial Planning Inc.’s portfolio, making the stock its 8th biggest holding. Keystone Financial Planning Inc.’s holdings in GSK were worth $10,175,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of GSK. Bogart Wealth LLC grew its position in shares of GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock valued at $83,000 after acquiring an additional 200 shares during the period. Natural Investments LLC lifted its position in GSK by 2.8% during the second quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company’s stock valued at $405,000 after purchasing an additional 211 shares in the last quarter. Grove Bank & Trust lifted its position in GSK by 3.8% during the third quarter. Grove Bank & Trust now owns 5,859 shares of the pharmaceutical company’s stock valued at $282,000 after purchasing an additional 215 shares in the last quarter. Canandaigua National Bank & Trust Co. grew its holdings in GSK by 3.7% during the third quarter. Canandaigua National Bank & Trust Co. now owns 6,185 shares of the pharmaceutical company’s stock valued at $298,000 after purchasing an additional 223 shares during the period. Finally, HF Advisory Group LLC grew its holdings in GSK by 3.5% during the second quarter. HF Advisory Group LLC now owns 7,578 shares of the pharmaceutical company’s stock valued at $397,000 after purchasing an additional 259 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GSK. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a research note on Thursday, July 30th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Berenberg Bank set a $60.00 price target on shares of GSK in a report on Tuesday, September 15th. Citigroup assumed coverage on shares of GSK in a research report on Friday, July 24th. They issued a “neutral” rating for the company. Finally, Weiss Ratings cut shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $56.50.

GSK Price Performance

Shares of GSK stock opened at $46.52 on Friday. The stock’s 50-day simple moving average is $50.12 and its 200-day simple moving average is $51.87. GSK PLC Sponsored ADR has a 52 week low of $42.85 and a 52 week high of $61.69. The company has a market capitalization of $94.09 billion, a price-to-earnings ratio of 14.55, a PEG ratio of 2.11 and a beta of 0.33. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81.

GSK (NYSE:GSK) last released its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%.The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter last year, the business posted $0.47 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts expect that GSK PLC Sponsored ADR will post 4.79 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a $0.4515 dividend. This represents a $1.81 annualized dividend and a yield of 3.9%. The ex-dividend date was Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. GSK’s dividend payout ratio is currently 55.31%.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: ViiV Healthcare’s long-acting HIV treatment Cabenuva met its primary endpoint by delivering superior viral suppression versus daily oral therapy in people with viremia. The result supports GSK’s HIV franchise and could strengthen Cabenuva’s commercial outlook. Cabenuva clinical trial results
• Positive Sentiment: GSK expanded its pipeline through a Wave Life Sciences collaboration focused on GalNAc-siRNA treatments for liver diseases and an AN2 Therapeutics tuberculosis research program backed by the Gates Foundation. The deals add potential longer-term growth opportunities beyond established products. GSK research partnerships
• Positive Sentiment: An analyst article described GSK’s transformation strategy—including more than 20 planned Phase III starts in 2026, reinvestment of cost savings into research and development and acquisitions, and active HIV portfolio management—as an attractive risk/reward proposition. This may support bullish sentiment, although execution risks remain. GSK strategic transformation analysis
• Neutral Sentiment: GSK launched a shingles-awareness campaign with Viola Davis aimed at adults aged 50 and older. The initiative could improve awareness of shingles risk and vaccination, but it is primarily educational and has no immediate financial guidance attached. GSK shingles education campaign
• Neutral Sentiment: GSK’s trading window closed ahead of its upcoming second-quarter results, leaving investors focused on the pending earnings release for updates on performance and guidance. GSK trading window before results
• Negative Sentiment: One valuation analysis argued that GSK could still trade below fair value despite the Cabenuva trial news, reflecting concerns about current earnings power and the company’s longer-term outlook. GSK valuation analysis

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.